Allopregnanolone as a Regenerative Therapeutic for Alzheimer's Disease (AD): A phase 2 proof-of-concept clinical trial using hippocampal volume as a surrogate endpoint

被引：0
|
作者：
Rivera, Gerson Hernandez [1 ]
Lopez, Claudia [1 ]
Raikes, Adam [1 ]
Rodgers, Kathleen [1 ]
Matthews, Dawn [2 ]
Schneider, Lon [3 ]
Brinton, Roberta [1 ]
机构：
[1] Univ Arizona, Ctr Innovat Brain Sci, Tucson, AZ USA
[2] ADM Diagnost, Northbrook, IL USA
[3] USC Sch Med, Los Angeles, CA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202953
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P8-6.008
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Allopregnanolone as regenerative therapeutic for Alzheimer's disease: Translational development and clinical promise
    Irwin, Ronald W.
    Brinton, Roberta Diaz
    PROGRESS IN NEUROBIOLOGY, 2014, 113 : 40 - 55
  • [2] Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease
    Koronyo, Yosef
    Biggs, David
    Barron, Ernesto
    Boyer, David S.
    Pearlman, Joel A.
    Au, William J.
    Kile, Shawn J.
    Blanco, Austin
    Fuchs, Dieu-Trang
    Ashfaq, Adeel
    Frautschy, Sally
    Cole, Gregory M.
    Miller, Carol A.
    Hinton, David R.
    Verdooner, Steven R.
    Black, Keith L.
    Koronyo-Hamaoui, Maya
    JCI INSIGHT, 2017, 2 (16)
  • [3] Functional imaging of hippocampal dysfunction among persons with Alzheimer's disease: a proof-of-concept study
    Arciniegas, David B.
    Tregellas, Jason R.
    Rojas, Donald C.
    Hewitt, Burlleen
    Anderson, C. Alan
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 779 - 783
  • [4] Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial
    Hernandez, Gerson D.
    Solinsky, Christine M.
    Mack, Wendy J.
    Kono, Naoko
    Rodgers, Kathleen E.
    Wu, Chun-Yi
    Mollo, Ana R.
    Lopez, Claudia M.
    Pawluczyk, Sonia
    Bauer, Gerhard
    Matthews, Dawn
    Shi, Yonggang
    Law, Meng
    Rogawski, Michael A.
    Schneider, Lon S.
    Brinton, Roberta D.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2020, 6 (01)
  • [5] Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial
    Videnovic, Aleksandar
    Amara, Amy W.
    Comella, Cynthia
    Schweitzer, Paula K.
    Emsellem, Helene
    Liu, Kris
    Sterkel, Amanda L.
    Gottwald, Mildred D.
    Steinerman, Joshua R.
    Jochelson, Philip
    Zomorodi, Katie
    Hauser, Robert A.
    MOVEMENT DISORDERS, 2021, 36 (10) : 2408 - 2412
  • [6] Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes
    Raikes, Adam C.
    Hernandez, Gerson D.
    Matthews, Dawn C.
    Lukic, Ana S.
    Law, Meng
    Shi, Yonggang
    Schneider, Lon S.
    Brinton, Roberta D.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
  • [7] A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    Chad J. Swanson
    Yong Zhang
    Shobha Dhadda
    Jinping Wang
    June Kaplow
    Robert Y. K. Lai
    Lars Lannfelt
    Heather Bradley
    Martin Rabe
    Akihiko Koyama
    Larisa Reyderman
    Donald A. Berry
    Scott Berry
    Robert Gordon
    Lynn D. Kramer
    Jeffrey L. Cummings
    Alzheimer's Research & Therapy, 13
  • [8] A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
    Swanson, Chad J.
    Zhang, Yong
    Dhadda, Shobha
    Wang, Jinping
    Kaplow, June
    Lai, Robert Y. K.
    Lannfelt, Lars
    Bradley, Heather
    Rabe, Martin
    Koyama, Akihiko
    Reyderman, Larisa
    Berry, Donald A.
    Berry, Scott
    Gordon, Robert
    Kramer, Lynn D.
    Cummings, Jeffrey L.
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [9] Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration
    Swerdlow, Neal R.
    Kotz, Juliana E.
    Joshi, Yash B.
    Talledo, Jo
    Sprock, Joyce
    Molina, Juan L.
    Huisa, Branko
    Huege, Steven F.
    Romero, Jairo Alberto
    Walsh, Michael J.
    Delano-Wood, Lisa
    Light, Gregory A.
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 84 (04) : 1431 - 1438
  • [10] Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    Chad J. Swanson
    Yong Zhang
    Shobha Dhadda
    Jinping Wang
    June Kaplow
    Robert Y. K. Lai
    Lars Lannfelt
    Heather Bradley
    Martin Rabe
    Akihiko Koyama
    Larisa Reyderman
    Donald A. Berry
    Scott Berry
    Robert Gordon
    Lynn D. Kramer
    Jeffrey L. Cummings
    Alzheimer's Research & Therapy, 14
12345